Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection
Loading...
Official URL
Full text at PDC
Publication date
2021
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
Citation
López Cano, J. J., González-Cela Casamayor, M. M., Andrés Guerrero, V. et al. «Liposomes as Vehicles for Topical Ophthalmic Drug Delivery and Ocular Surface Protection». Expert Opinion on Drug Delivery, vol. 18, n.o 7, julio de 2021, pp. 819-47. DOI.org (Crossref), https://doi.org/10.1080/17425247.2021.1872542.
Abstract
Introduction: The development of ophthalmic formulations able to deliver hydrophilic and hydrophobic drugs to the inner structures of the eye and restore the preocular tear film has been a leading topic of discussion over the last few years. In this sense, liposomes represent a suitable strategy to achieve these objectives in ocular drug delivery.
Areas covered: Knowledge of the different physiological and anatomical eye structures, and specially the ocular surface are critical to better understanding and comprehending the characteristics required for the development of topical ophthalmic liposomal formulations. In this review, several features of liposomes are discussed such as the main materials used for their fabrication, basic structure and preparation methods, from already established to novel techniques, allowing the control and design of special characteristics. Besides, physicochemical properties, purification processes and strategies to overcome delivery or encapsulation challenges are also presented.
Expert opinion: Regarding ocular drug delivery of liposomes, there are some features that can be redesigned. Specific biocompatible and biodegradable materials presenting therapeutic properties, such as lipidic compounds or polymers significantly change the way of tackling ophthalmic diseases.
Besides, liposomes entail an effective, safe and versatile strategy for the treatment of diseases in the clinical practice.
Description
Funding: Research Group UCM 920415, Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal), ISCIII-FEDER RETICS (OFTARED) (RD16/0008/0009 and RD16/0008/0004), FEDER-CICYT FIS-PI17/00079 and PI17/00466